Health ministry questions reliability of vasculitis drug approval data

·1h ago
Share:PostShare

Tavneos was launched in Japan in 2022 after being approved by the ministry. Its package insert listed liver dysfunction as a serious side effect.

T

The Japan Times

Original source

Read full story

Related Stories

Headlines and briefs on this site are for information only. Always verify details on the original source or live status page.

Read Disclaimer